The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The usefulness of dogs and monkeys in predicting potential qualitative drug toxicity in man was examined retrospectively for twenty‐five anticancer compounds of diverse chemical and functional classification. It was found that the large animal screen served to alert the physician to a significant proportion of the total spectrum of drug effects, which were encountered during the clinical use of a new toxic compound. The dog and monkey correctly predicted bone marrow depression, gastrointestinal disturbance, and hepatotoxicity for each drug producing these effects in the clinic; in the case of renal, cardiovascular, and neuromuscular toxicity, however, the large animal screen failed in each instance to predict one drug that produced these toxicities in man. The correct predictions were accomplished at the expense of a high percentage of false positives, which resulted from the necessity of using severely toxic dose levels in order to demonstrate all potential toxicities inherent in any compound. While organ system toxicity observed during an animal study can never be disregarded, it should be viewed with an understanding of certain limitations of animal toxicologic data. While toxicity may develop in man in an organ system predicted susceptible by an animal, a different specific clinical or chemical parameter may be involved. The adverse reaction may appear in man at a greater or lesser dose level or may follow a different order of appearance in relationship to the total spectrum of qualitative toxicity inherent in the compound.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Schein present an analysis of 25 anticancer drug toxicities in several papers [83–86], each paper combining the analysis with other information.”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [86]
Citations
Cites
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Self-citationMitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA
Iyer, V. N., & Szybalski, W. (1964) · Science · doi:10.1126/science.145.3627.55 · Cited by 570
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Studies on the Diabetogenic Action of Streptozotocin (NSC37917)
Raikieten, N. (1963) · Medical Entomology and Zoology · Cited by 443
The use of body surface area as a criterion of drug dosage in cancer chemotherapy.
Pinkel, D. P. (1958) · PubMed · Cited by 344
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.
Vt, D. V., Pp, C., Owens, A. H., Gold, G. L., Mj, K., & Edmonson, J. H. (1965) · PubMed · Cited by 218
Clinical studies with 5-fluorouracil.
Curreri, A. R., Ansfield, F. J., McIver, F. A., Waisman, H. A., & Heidelberger, C. (1958) · PubMed · Cited by 206
Schein, P. S., Cooney, D. A., & Vernon, M. L. (1967) · PubMed · Cited by 206
Self-citationComparative patterns of drug metabolism.
Williams, R. T. (1967) · PubMed · Cited by 170
A Syllabus of Laboratory Examinations in Clinical Diagnosis
Perry, C. A., Humphrey, J., & Brownlee, M. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.8_pt_1.1010-a · Cited by 159
GOLDBERG, I. H. (1965) · The American Journal of Medicine · doi:10.1016/0002-9343(65)90094-x · Cited by 144
Characteristics of new cell lines derived from Burkitt lymphomas
Nadkarni, J. S., Nadkarni, J. J., Clifford, P., Manolov, G., Fenyõ, É. M., & Klein, E. (1969) · Cancer · doi:10.1002/1097-0142(196901)23:1<132::aid-cncr2820230116>3.0.co;2-7 · Cited by 135
Biochemical and pharmacological studies with 1-β-d-arabinofuranosylcytosine in man
Creasey, W. A., Papac, R. J., Markiw, M. E., Calabresi, P., & Welch, A. D. (1966) · Biochemical Pharmacology · doi:10.1016/0006-2952(66)90186-9 · Cited by 121
BIOLOGICAL AND BIOCHEMICAL PROPERTIES OF THE ANALOGUE ANTIBIOTIC TUBERCIDIN
Acs, G., Reich, E., & Mori, M. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.52.2.493 · Cited by 119
THE TOXICITY OF PENICILLIN AS PREPARED FOR CLINICAL USE
Hamre, D. M., Rake, G. W., McKee, C. M., & MacPhillamy, H. B. (1943) · The American Journal of the Medical Sciences · doi:10.1097/00000441-194311000-00011 · Cited by 113
Antitumor activity of triazenoimidazoles
Shealy, Y. F., Montgomery, J. A. J., & Laster, W. R. (1962) · Biochemical Pharmacology · doi:10.1016/0006-2952(62)90130-2 · Cited by 82
The appendix in relation to neoplastic disease
McVay, J. R. (1964) · Cancer · doi:10.1002/1097-0142(196407)17:7<938::aid-cncr2820170714>3.0.co;2-n · Cited by 78
Clinical evaluation of cancer chemotherapy with 5-fluorouracil
Vaitkevicius, V. K., Brennan, M. J., Beckett, V. L., Kelly, J. E., & Talley, R. W. (1961) · Cancer · doi:10.1002/1097-0142(196101/02)14:1<131::aid-cncr2820140118>3.0.co;2-3 · Cited by 73
Iriarte, P. V., Hananian, J., & Cortner, J. A. (1966) · Cancer · doi:10.1002/1097-0142(196609)19:9<1187::aid-cncr2820190902>3.0.co;2-t · Cited by 64
Meningeal leukemia.A follow-up study
Nies, B. A., Thomas, L. B., & Freireich, E. J. (1965) · Cancer · doi:10.1002/1097-0142(196505)18:5<571::aid-cncr2820180506>3.0.co;2-h · Cited by 59
Meningeal leukemia.A follow-up study
Nies, B. A., Thomas, L. B., & Freireich, E. J. (1965) · Cancer · doi:10.1002/1097-0142(196505)18:5<546::aid-cncr2820180503>3.0.co;2-e · Cited by 59
Forecasting Drug Effects in Man from Studies in Laboratory Animals
Litchfield, J. T. (1961) · JAMA · doi:10.1001/jama.1961.73040270021004c · Cited by 57
Cellular Effects of Anticancer Drugs
Karnofsky, D. A., & Clarkson, B. (1963) · Annual Review of Pharmacology · doi:10.1146/annurev.pa.03.040163.002041 · Cited by 52
Predicting anticancer drug effects in man from laboratory animal studies
Owens, A. H. (1962) · Journal of Chronic Diseases · doi:10.1016/0021-9681(62)90003-6 · Cited by 47
Species differences and the clinical trial of new drugs: A review
Koppanyi, T., & Avery, M. A. (1966) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196672250 · Cited by 46
Wheeler, G. P., & Bowdon, B. J. (1965) · PubMed · Cited by 39
Mitomycin-C in the therapy of far-advanced malignant tumors
Manheimer, L. H., & Vital, J. B. (1966) · Cancer · doi:10.1002/1097-0142(196602)19:2<207::aid-cncr2820190211>3.0.co;2-6 · Cited by 37
Clinical Studies of 6-Azauracil
Shnider, B. I., Frei, E., Tuohy, J. H., Gorman, J. G., Freireich, E. J., Brindley, C. O., & Clements, J. A. (1960) · Cancer Research · Cited by 36
Synthesis of Potential Anticancer Agents. XXIII. 9-Aminohypoxanthine and Related Compounds
Montgomery, J. A. J., & Temple, C. (1960) · Journal of the American Chemical Society · doi:10.1021/ja01502a037 · Cited by 33
STUDIES ON THE PHARMACOLOGY OF 6-AZAURACIL
Welch, A. D., Handschumacher, R. E., & Jaffe, J. J. (1960) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)25820-7 · Cited by 32
Mithramycin-human toxicology and preliminary therapeutic investigation.
CURRERI, A. R., & Ansfield, F. J. (1960) · PubMed · Cited by 32
Some pharmacological consequences of species variation in rates of metabolism.
Bb, B., & Reid, W. D. (1967) · PubMed · Cited by 30
Cytosine arabinoside (NSC-63878) in acute leukemia in children.
Jp, H., Çevik, N. N., & Ml, M. (1966) · PubMed · Cited by 29
The clinical evaluation of PA-144(mithramycin) in solid tumors of adults.
Gw, P., Ds, W., & Cb, J. (1960) · PubMed · Cited by 14
Initial toxicity study of sangivamycin (NSC-65346).
Cavins, J. A., Hall, T. C., Olson, K. B., Khung, C. L., Horton, J., Colsky, J., & Shadduck, R. K. (1967) · PubMed · Cited by 14
Solid Tumor Chemotherapy With Mitomycin C
Watne, A. L. (1967) · Archives of Surgery · doi:10.1001/archsurg.1967.01330140013003 · Cited by 13
Bodey, G. P., Brodovsky, H. S., Isassi, A. A., Samuels, M. L., & Freireich, E. J. (1968) · PubMed · Cited by 13
Phase II study of azotomycin (NSC-56654).
Weiss, A. J., Ramírez, G. H., Grage, T. B., Strawitz, J., Goldman, L. H., & Downing (1968) · PubMed · Cited by 11
Oettgen, H. F., Clifford, P., & Jh, B. (1963) · PubMed · Cited by 10
The clinical excursion into 5-fluorouracil
Schneiderman, M. A. (1962) · Journal of Chronic Diseases · doi:10.1016/0021-9681(62)90012-7 · Cited by 9
Effect of 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea on Saccharomyces cerevisiae.
Gale, G. R. (1965) · Experimental Biology and Medicine · doi:10.3181/00379727-119-30361 · Cited by 9
Purin-6-yltrimethylammonium chloride: A new purine antimetabolite
Horwitz, J. P., & Vaitkevicius, V. K. (1961) · Cellular and Molecular Life Sciences · doi:10.1007/bf02156417 · Cited by 8
Effects of a pyrimidine analog, 6-azauracil, on rat electroencephalogram and maze running ability
Morris, N. R., & Glaser, G. H. (1959) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(59)90016-1 · Cited by 8
Effect of 1,3-bis-(2-chloroethyl)-l-nitrosourea on ehrlich ascites tumor cells
Gale, G. R. (1965) · Biochemical Pharmacology · doi:10.1016/0006-2952(65)90259-5 · Cited by 7
Nathanson, L., Tc, H., Rutenberg, A., & Shadduck, R. K. (1967) · PubMed · Cited by 7
Preliminary studies with dibromomannitol (NSC-94100) in patients with chronic myelogenous leukemia.
Ar, C., El, C., & Pp, C. (1967) · PubMed · Cited by 7
The Predictive Value of Animal Toxicity Studies Carried Out on New Drugs
Golberg, L. (1963) · The Journal of New Drugs · doi:10.1002/j.1552-4604.1963.tb00054.x · Cited by 6
The clinical effects of mitomycin C by continuous intravenous administration.
Miller, E. B., Rd, S., & Chryssochoos, T. (1962) · PubMed · Cited by 5
Phthalanilides-a new group of potential antitumor agents.
Schepartz, S. A., Wodinsky, I., & Leiter, J. (1962) · PubMed · Cited by 5
PREDICTABILITY OF CONVENTIONAL ANIMAL TOXICITY TESTS
Litchfield, J. T. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb12267.x · Cited by 4
Phase 1 studies of porfiromycin (NSC-56410).
Foley, H. T., Shnider, B. I., Gold, G. L., Matias, P. I., Colsky, J., & Sp, M. (1967) · PubMed · Cited by 4
PHASE I STUDY OF AZOTOMYCIN (NSC-56654).
Ansfield, F. J. (1965) · PubMed · Cited by 3
Comparative toxicity of drugs.
Eh, D. (1967) · PubMed · Cited by 2
Phase I clinical study of 2-(dimethylamino)-3',4'-dihydroxyacetophenone, hydrochloride (NSC-62512).
Jh, M., Wl, W., Ansfield, F. J., Rochlin, D. B., & Grage, T. B. (1968) · PubMed · Cited by 1
Cited by
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
“(12) showed that for antineoplastic drugs, lethal doses to 10% (LD10) of rodents and maximum tolerated doses (MTD) in nonrodents correlated with the human MTD when the doses were normalized to the same administration schedule and expressed in terms of BSA in mg/m(2).”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
Hayes' Principles and Methods of Toxicology
(2014) · CRC Press eBooks · doi:10.1201/b17359 · Cited by 280
First dose of potential new medicines to humans: how animals help
Greaves, P., Williams, A., & Eve, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1329 · Cited by 243
“The dog data were better correlated with human adverse effects in the study of 25 anticancer drugs by Schein et al.(16).”
Background
Metadata
- Authors
- Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., & Rall, D. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Newman, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1970-01
- Volume
- 11
- Issue
- 1
- Pages
- 3-40
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2415622130
- Cited by
- 146
- References
- 53
- Citations by year
- 2024: 1 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- anticancer agents, drug toxicity prediction, dogs, monkeys, bone marrow depression, hepatotoxicity, gastrointestinal toxicity, nephrotoxicity, cardiotoxicity, neuromuscular toxicity, false positives, animal-to-human extrapolation, adverse drug reactions
- MeSH terms
- Animals, Haplorhini, Antimetabolites, Antineoplastic Agents, Bone Marrow Diseases, Cardiovascular Diseases, Dogs, Eye Manifestations, Gastrointestinal Diseases, Humans, Kidney Diseases, Lymphatic Diseases, Lymphopenia, Methods, Neurologic Manifestations, Respiratory Tract Diseases, Skin Manifestations, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.